Singapore markets closed
Straits Times Index
3,410.81 -29.07 (-0.85%) Nikkei
40,912.37 -1.28 (-0.00%) Hang Seng
17,799.61 -228.67 (-1.27%) FTSE 100
8,203.93 -37.33 (-0.45%) Bitcoin USD
57,955.63 +1,551.84 (+2.75%) CMC Crypto 200
1,208.43 -0.27 (-0.02%)
Bristol-Myers Squibb Company (BMY.MX)
Mexico - Mexico Delayed price. Currency in MXN
Add to watchlist
At close: 12:47PM CST
| Previous close | 725.00 |
| Open | 717.52 |
| Bid | 713.60 x 1400 |
| Ask | 730.99 x 3800 |
| Day's range | 713.00 - 717.52 |
| 52-week range | 676.60 - 1,093.85 |
| Volume | |
| Avg. volume | 4,607 |
| Market cap | 1.456T |
| Beta (5Y monthly) | 0.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 43.47 (6.10%) |
| Ex-dividend date | 05 Jul 2024 |
| 1y target est | N/A |
- Business Wire
Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
PRINCETON, N.J., June 21, 2024--Bristol Myers Squibb Announces U.S. FDA Accelerated Approval of KRAZATI® (adagrasib) in Combination with Cetuximab for Adult Patients with...
- Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Subcutaneous Nivolumab
PRINCETON, N.J., June 21, 2024--European Medicines Agency Validates Bristol Myers Squibb's Application for Subcutaneous Nivolumab
- Business Wire
Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
PRINCETON, N.J., June 20, 2024--Bristol Myers Squibb to Report Results for Second Quarter 2024 on July 26, 2024
© 2024 Yahoo. All rights reserved.